Midazolam B. Braun (Midazolam Hydrochloride)

Midazolam enhances the activity of the inhibitory neurotransmitter GABA at the GABA‑A receptor. By increasing chloride ion influx into neurons, it hyperpolarizes the cell membrane, leading to reduced neuronal excitability and producing sedation, anxiolysis, hypnosis, and anticonvulsant effects.

The specific dose of Midazolam B. Braun is determined by the prescribing clinician based on the patient’s age, weight, clinical condition, and route of administration. Healthcare professionals tailor the regimen to achieve the desired level of sedation or seizure control while monitoring safety.

Midazolam’s safety in pregnancy and lactation is not well established. It should be used only when the potential benefit to the mother outweighs any possible risk to the fetus or infant, and the decision must be made by a qualified healthcare provider.

To order Midazolam B. Braun, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Midazolam has a rapid onset and short duration of action compared with many benzodiazepines such as diazepam or lorazepam. This makes it especially suitable for procedural sedation and acute seizure control, whereas longer‑acting agents are often preferred for chronic anxiety or insomnia.

Midazolam B. Braun should be stored at room temperature, below 25 °C, in its original packaging. Protect the product from excessive light, moisture, and physical damage. Do not freeze or refrigerate unless the label specifically indicates a cold‑chain requirement.

Midazolam B. Braun is administered by a healthcare professional via intramuscular, intravenous, or rectal routes, depending on the clinical situation. The route, dose, and rate of administration are selected by the prescriber to achieve the intended level of sedation or seizure control.

The most serious risks include severe respiratory depression, profound hypotension, anaphylaxis, and paradoxical reactions such as agitation or aggression. Continuous monitoring of respiratory and cardiovascular status is essential, especially when higher doses or concurrent depressant drugs are used.

Midazolam B. Braun is contraindicated in patients with known hypersensitivity to midazolam or any benzodiazepine component, and it should be avoided in individuals with severe respiratory insufficiency, acute narrow‑angle glaucoma, or those taking certain interacting medications without appropriate monitoring.